The CarboMedics cardiac prosthesis (CarboMedics, Inc., Austin, Tex.) is a relatively new, low-profile bileaflet prosthesis. We report the results of a prospective mid-term evaluation of 426 CarboMedics prostheses implanted at our institution. Three hundred fifty patients had CarboMedics prostheses implanted in the mitral (n = 125), aortic (n = 149), or aortic and mitral positions (n = 76). Hospital mortality was 5.2 %. Follow-up was 98% complete, with 478 patient/years and a mean follow-up of 19 months (range 1 to 42 months). Actuarial freedom from complications were calculated as follows (linearized rates in parentheses): late mortality 97 % +/- 0.77 % (2.7 %), thromboembolism 98 % +/- 0.4 % (0.5 %), anticoagulation-related hemorrhage 98.6 % +/- 0.4 % (0.4 %), nonstructural dysfunction 98.5 % +/- 0.6 (0.2 %), valve-related mortality 91.5 % +/- 0.7 (0.5 % ), valve failure 90.9 % +/- 1 % (0.7 %), treatment failure 92.8 % +/- 0.8 % (0.7 %), and all valve-related morbidity and mortality 90 % +/- 2 % (2.6 %). According to our results, the CarboMedics valve has a low rate of complications that further improves the quality of life in patients with heart valve prostheses.
MIDTERM FOLLOW-UP AFTER HEART-VALVE REPLACEMENT WITH CARBOMEDICS BILEAFLET PROSTHESES
DE LUCA TUPPUTI SCHINOSA, Luigi;
1993-01-01
Abstract
The CarboMedics cardiac prosthesis (CarboMedics, Inc., Austin, Tex.) is a relatively new, low-profile bileaflet prosthesis. We report the results of a prospective mid-term evaluation of 426 CarboMedics prostheses implanted at our institution. Three hundred fifty patients had CarboMedics prostheses implanted in the mitral (n = 125), aortic (n = 149), or aortic and mitral positions (n = 76). Hospital mortality was 5.2 %. Follow-up was 98% complete, with 478 patient/years and a mean follow-up of 19 months (range 1 to 42 months). Actuarial freedom from complications were calculated as follows (linearized rates in parentheses): late mortality 97 % +/- 0.77 % (2.7 %), thromboembolism 98 % +/- 0.4 % (0.5 %), anticoagulation-related hemorrhage 98.6 % +/- 0.4 % (0.4 %), nonstructural dysfunction 98.5 % +/- 0.6 (0.2 %), valve-related mortality 91.5 % +/- 0.7 (0.5 % ), valve failure 90.9 % +/- 1 % (0.7 %), treatment failure 92.8 % +/- 0.8 % (0.7 %), and all valve-related morbidity and mortality 90 % +/- 2 % (2.6 %). According to our results, the CarboMedics valve has a low rate of complications that further improves the quality of life in patients with heart valve prostheses.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.